GFAP and Alzheimer disease: Recently, plasma AD biomarkers, such as phosphorylated-tau (p-tau), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL), have been developed to reflect core AD pathology, neuroinflammation, and neurodegeneration, respectively17.